In a report released today, Laura Chico from Wedbush maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report), with a price ...

It was almost an extraordinary scene in front of the White House. As Tesla shares have been tanking since the year began, President Donald Trump held remarks outside of the White House with the ...

Tesla's lower-cost vehicle is supposed to begin production by June at the latest. Analysts tell BI the launch is "crucial" ...

Musk pumped $270 million into Trump's campaign heading into the 2024 election, appeared on stage with him and cheered Trump's ...

Transamerica Pyramid Center has become a global tech, finance and AI hub, and AppDirect joins tenants such as Blockchain Capital, Wedbush and NextAxiom ... we have preserved its legacy as a global ...

NVDA stock rose after hours as Nvidia's earnings results beat estimates. Blackwell chips brought in $11 billion for Nvidia, ...

Nvidia exceeded Wall Street’s expectations as it closed out 2024, achieving stunning sales and profit growth — and much of ...

Dan Ives, Wedbush global head of technology research, joins 'Power Lunch' to discuss Apple's U.S. investment and Microsoft's AI spending concerns in the market.

However, Wedbush’s team said Musk has a good track record of balancing multiple initiatives and accelerating innovation at Tesla. Put simply, Wedbush views these as containable brand issues that ...

Wedbush currently has a “Outperform” rating and a $36.00 target price on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share.

Investing.com -- Tesla's stock has faced continued pressure in 2025, but Wedbush analysts remain bullish, maintaining their Outperform rating and $550 price target on the stock. While concerns ...

Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing exchange-traded fund market. With more than 7K ETFs listed globally, collectively managing over $10T in ...